Psychedelics’ Political Tailwind, Translated

Three things are true about the psychedelics-for-addiction conversation as of mid-May 2026. The Trump administration has signed an executive order accelerating US-led psychedelic research, with a specific emphasis on ibogaine — the West African plant alkaloid that has shown signal for opioid use disorder and is currently a Schedule I controlled substance. The FDA on April 24 granted national priority vouchers to three psychedelic compounds: Compass Pathways’ COMP360 (psilocybin) for treatment-resistant depression; a second psilocybin program for major depressive disorder; and methylone for PTSD. Compass Pathways now expects to submit a full NDA this summer with FDA Commissioner Marty Makary publicly targeting a late summer or fall decision.

And Lykos Therapeutics — which 18 months ago looked like the first psychedelic FDA approval and instead absorbed an outright rejection of its MDMA-PTSD therapy — has reduced its workforce by approximately 75%, cutting across clinical operations, regulatory affairs, and commercial readiness.

What these three facts describe, together, is a field reorganizing around what the FDA is actually willing to approve in 2026 — not around what the 2022–2024 hype cycle promised. The ibogaine emphasis in the executive order is the most addiction-specific signal: an OUD treatment whose evidence base is real but small, with a regulatory pathway that has historically been treated as politically impossible. The Compass NDA timeline is the most near-term signal: the first psilocybin decision in this country may be made before the end of the year.

Why this matters for people in recovery

Promising and approved are not the same word. Ibogaine, psilocybin, and MDMA are still Schedule I controlled substances. They are not available as treatment outside specific research settings, and the evidence base for any of them as an addiction treatment is earlier than the headlines often suggest. If you are in recovery and you encounter someone presenting psychedelic-assisted therapy as “the next thing” — be a careful consumer. Ask what protocol, ask what licensure, ask what the comparator was. Hope is real. So is harm. Both are possible in the same room.

Need help right now?

• 988 Suicide & Crisis Lifeline
• Find treatment: Rize Recovery